Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
暂无分享,去创建一个
A. Olshen | J. Teruya-Feldstein | S. Ely | C. Hedvat | S. Nimer | N. Kalakonda | R. Comenzo | Julie Teruya-Feldstein | Stephen D Nimer | Adam B Olshen | K. Osman | Yana Zhang | Raymond L Comenzo | Cyrus V Hedvat | Scott A Ely | Keren Osman | Yana Zhang | Nagesh Kalakonda | Keren Osman
[1] W. Berdel,et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.
[2] M. Potter,et al. Induction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane) , 1969, Nature.
[3] D. Leroith,et al. Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.
[4] R. Bataille,et al. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. , 2001, Blood.
[5] R. Timpl,et al. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. , 1998, Cell adhesion and communication.
[6] M. Albitar. Angiogenesis in Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2002, Acta Haematologica.
[7] H. Zhang,et al. Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. , 1996, Journal of immunology.
[8] K. Anderson,et al. Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays , 2002, Oncogene.
[9] S. Rudikoff,et al. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. , 2000, Blood.
[10] W. Bellamy. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. , 2001, Seminars in oncology.
[11] P. L. Bergsagel,et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[12] Cheng Li,et al. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.
[13] J. V. van Mourik,et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. , 1992, International immunology.
[14] J. Miyazaki,et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] B. Klein,et al. Interleukin-6 in human multiple myeloma. , 1995, Blood.
[16] Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.
[17] G. Gray,et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. , 1990, Science.
[18] G. Pinkus,et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. , 1997, Blood.
[19] K. Anderson,et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.
[20] T. Rasmussen,et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma , 2002, British journal of haematology.
[21] C. Duan. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. , 2002, The Journal of endocrinology.
[22] N. Kay,et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules , 2002, Leukemia.
[23] D. Govender,et al. CD31 (JC70) expression in plasma cells: an immunohistochemical analysis of reactive and neoplastic plasma cells. , 1997, Journal of clinical pathology.
[24] O. Podhajcer,et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.
[25] D. Ribatti,et al. Bone Marrow Angiogenesis and Plasma Cell Angiogenic and Invasive Potential in Patients with Active Multiple Myeloma , 2002, Acta Haematologica.
[26] Masato Nakamura,et al. Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. , 2002, International journal of molecular medicine.
[27] S. Tura,et al. Antiangiogenic Therapy in Multiple Myeloma , 2001, Acta Haematologica.
[28] H. F. Barker,et al. The role of adhesion molecules in multiple myeloma. , 1997, Leukemia & lymphoma.
[29] A. Hidalgo,et al. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.
[30] D. Ribatti,et al. Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44 , 1995, American journal of hematology.
[31] J. Norton,et al. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. , 2001, Blood.
[32] J. Berenson. Advances in the biology and treatment of myeloma bone disease. , 2002, Seminars in oncology.
[33] S. Bauer,et al. Increased expression of myc-related oncogene mRNA characterizes most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[34] T. Grogan,et al. Long-term engraftment of fresh human myeloma cells in SCID mice. , 1992, Blood.
[35] R. Strieter,et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.
[36] W. Dalton,et al. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance , 2000, Current opinion in oncology.
[37] K. Calame,et al. Plasma cells: finding new light at the end of B cell development , 2001, Nature Immunology.
[38] D. Clemmons,et al. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Chilosi,et al. Human myeloma cells express the CD38 ligand CD31 , 1999, British journal of haematology.
[40] H. Namba,et al. Tie-2 and angiopoietin-1 expression in human thyroid tumors. , 2002, Thyroid : official journal of the American Thyroid Association.
[41] K. Kinzler,et al. Genes expressed in human tumor endothelium. , 2000, Science.
[42] A. Feller,et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. , 2002, Leukemia research.
[43] A. Falus,et al. Mouse plasmacytoma: an experimental model of human multiple myeloma. , 2001, Haematologica.
[44] J. D. Vos,et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays , 2002, Oncogene.
[45] J. Woodgett,et al. A molecular compendium of genes expressed in multiple myeloma. , 2002, Blood.
[46] JS Damiano,et al. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and γ-irradiation , 2001, Leukemia.
[47] P. L. Bergsagel,et al. Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.
[48] H. Schuurman,et al. The SCID mouse as a model for multiple myeloma , 1995, British journal of haematology.
[49] John Crowley,et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.
[50] R. Bataille,et al. Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells , 1999, British journal of haematology.
[51] D Puthier,et al. High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.
[52] V. Cheng,et al. Extramedullary Plasmacytoma of the Head and Neck: A CLINICOPATHOLOGIC STUDY OF 20 CASES , 1982, Medicine.
[53] John Calvin Reed,et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. , 1998, Cancer research.
[54] D. Ribatti,et al. Bone marrow angiogenesis in patients with active multiple myeloma. , 2001, Seminars in oncology.